Document is current
Any future updates will be listed below
-
Authors
Holmes, Chris E.
Davis, George A.
Taatjes-Sommer, Heidi S.
Sai-Hardebeck, Naomi E.
Callas, Peter W.
Chidobem, Ikechukwu
Thomas, Ryan
Schneider, David J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05240508 at ClinicalTrials.govDocuments that mention this clinical trial
Platelet FcɣRIIa: a novel biomarker of risk for thromboembolism and death in cancer
https://doi.org/10.1007/s11239-026-03315-2
-
Funding
Funding for this research was provided by:
NIH (R21 20231130)
- License Information
-
More Information
Article History
Received: 16 March 2026
Accepted: 30 April 2026
First Online: 18 May 2026
Declarations
:
: David J Schneider is named inventor on patents (US 10,502,737, US 11,747,335 B2) that propose the use of FcɣRIIa for assaying platelet reactivity and treatment selection. Chris E Holmes and David J. Schneider are named inventors on a pending patent application that proposes use of FcɣRIIa for assessing risk for venous thromboembolism and cancer progression. David J. Schneider is a founder of Prolocor.
: The research protocol and consent were reviewed and approved by the University of Vermont Institutional Review Board.
: All participating subjects provided written informed consent.
: Not applicable.
